A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer

Trial Profile

A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Cervical cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 23 Nov 2017 to 31 Dec 2018.
    • 26 Jul 2017 Planned primary completion date changed from 23 Nov 2017 to 31 Dec 2018.
    • 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top